UT Health San Antonio and the American Association for Cancer Research are co-sponsors of the 2022 San Antonio Breast Cancer Symposium (SABCS), December 6-10, 2022, at the Henry B. Gonzalez Convention Center.

SABCS features the latest research in the prevention, diagnosis, and treatment of premalignant breast disease and breast cancer, including data from late-breaking clinical trials. Each year, the symposium attracts thousands of basic scientists, physician-scientists, clinical investigators, breast care providers, and advocates from around the world.

SABCS 2022 PRESS PROGRAM

The San Antonio Breast Cancer Symposium (SABCS) official press program includes three press conferences featuring eleven newsworthy studies from the symposium. The press program also included news releases on two additional abstracts.

Press Conference I

SABCS co-director Virginia Kaklamani, MD, UT Health San Antonio, moderated the first press conference on Tuesday, December 6.

View the press conference

The following studies were presented:

Black Women With Breast Cancer May Have Worse Outcomes Than Peers Despite Similar Genetic Recurrence Scores

• Presented by Yara Abdou, MD, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center

Study Finds Racial Disparity in Pro-metastatic Tumor Microenvironment Among Women With Residual Breast Cancer After Neoadjuvant Chemotherapy

• Presented by Maja H. Oktay, MD, PhD, Montefiore Einstein Cancer Center and Albert Einstein College of Medicine

A Genomic Assay May Predict Long-term Prognosis in Premenopausal Patients With Hormone Receptor-positive Early-stage Breast Cancer

• Presented by Ruth O’Regan, MD, University of Rochester

First-line Ribociclib Plus Endocrine Therapy May Be More Effective Than Combination Chemotherapy in Patients With Aggressive Breast Cancer

• Presented by Yen-Shen Lu, MD, PhD, National Taiwan University Hospital

Press Conference Ii

SABCS co-director Carlos Arteaga, MD, FAACR, UT Southwestern Harold C. Simmons Comprehensive Cancer Center, moderated the second press conference on Wednesday, December 7.

View the press conference

The following studies were presented:

T-DXd Yields Superior Outcomes Over Chemotherapy-based Regimens in Patients Previously Treated with T-DM1

• Presented by Ian Krop, MD, PhD, Yale Cancer Center

T-DXd Yields Longer Overall Survival than T-DM1 in Patients with HER2-positive Metastatic Breast Cancer

• Presented by Sara Hurvitz, MD, David Geffen School of Medicine at the University of California Los Angeles and Jonsson Comprehensive Cancer Center

Neoadjuvant Trastuzumab Deruxtecan Shows Clinical Activity in Patients With HER2-low Breast Cancer

• Presented by Aditya Bardia, MD, MPH, Mass General Cancer Center, Harvard Medical School

Press Conference III

SABCS co-director Carlos Arteaga, MD, FAACR, UT Southwestern Harold C. Simmons Comprehensive Cancer Center, moderated the third and final press conference on Thursday, December 8.

View the press conference

The following studies were presented:

Camizestrant May Be Superior to Fulvestrant in Patients With Hormone Receptor-positive, HER2-negative Breast Cancer

•  Presented by Mafalda Oliveira, MD, PhD, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology

Adding Capivasertib to Fulvestrant Improves Progression-free Survival in Patients With Advanced Hormone Receptor-positive Breast Cancer

•  Presented by Nicholas Turner, MD, PhD, The Institute of Cancer Research, and The Royal Marsden NHS Foundation Trust

Treatment Decision Guided by Circulating Tumor Cell Count May Improve Long-term Outcomes for Patients with Metastatic Breast Cancer

• Presented by François-Clément Bidard, MD, PhD, Institut Curie and Versailles Saint-Quentin University

Breast Cancer Patients Who Interrupted Endocrine Therapy to Pursue Pregnancy Did Not Experience Worse Short-term Recurrence Rates

• Presented by Ann Partridge, MD, MPH, Dana-Farber Cancer Institute and Harvard Medical School

Additional Press Releases

Breast-conserving Therapy May be a Treatment Option for Some Patients with Multiple Breast Lesions

• Presented by Judy C. Boughey, MD, Mayo Clinic

Genetic Profiling May Identify Patients with Breast Cancer Who Can Safely Omit Radiation Therapy After Breast-conserving Surgery

• Presented by Per Karlsson, MD, Sahlgrenska Comprehensive Cancer Center and the University of Gothenburg

#SABCS22